alexa Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Clinical & Experimental Pharmacology

Author(s): Mulder H, Heerdink ER, van Iersel EE, Wilmink FW, Egberts AC

Abstract Share this page

Abstract BACKGROUND: Despite a large number of studies investigating the potential clinical relevance of CYP2D6 genotyping in preventing treatment failure (eg, insufficient efficacy and/or unacceptable adverse effects), the prevalence of patients using drugs metabolized by that isoenzyme is relatively unknown. OBJECTIVE: To investigate the prevalence of patients in different populations using drugs metabolized by CYP2D6. METHODS: In this cross-sectional study, 6 different patient populations were investigated: general, general hospital, geriatric, psychogeriatric, psychiatric, and mentally retarded. From every population, 150 adults using at least one drug were randomly selected. Primary outcome was the prevalence of patients using at least one drug metabolized by CYP2D6. The prevalence of patients using at least one CYP2D6 substrate in different populations was compared with the general population using chi(2) statistics. Data were expressed as a relative risk with a 95\% confidence interval. RESULTS: Patients from the general hospital (RR 1.81; 95\% CI 1.26 to 2.62), geriatric patients (RR 2.16; 95\% CI 1.26 to 2.62), psychogeriatric patients (RR 2.31; 95\% CI 1.63 to 3.27), and psychiatric patients (RR 2.44; 95\% CI 1.73 to 3.44) were treated more frequently with at least one drug metabolized by CYP2D6 compared with patients in the general population. Approximately 50\% of psychiatric (52\%), psychogeriatric (49\%), and geriatric (46\%) patients used at least one drug metabolized by CYP2D6. In total, 416 drugs metabolized by CYP2D6 were prescribed, with 257 (62\%) of these classified as an antidepressant (Anatomical and Therapeutic Chemical [ATC] category N06A) or antipsychotic (ATC N05A). CONCLUSIONS: Several patient populations (eg, psychiatric, psychogeriatric, geriatric) have a high prevalence of patients treated with at least one drug metabolized by CYP2D6. This study does not provide evidence regarding the clinical evidence of CYP2D6 genotyping, but shows that, if CYP2D6 genotyping is relevant for patient care, the highest probability of cost-effectiveness will, most likely, be in specific populations. This article was published in Ann Pharmacother and referenced in Journal of Clinical & Experimental Pharmacology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords